The information contained in this online site (the "Service") is presented in summary form only and intended to provide a broad understanding and knowledge of healthcare topics. The information should not be considered complete and should not be used in place of a visit, call, consultation, or advice of your physician or other healthcare provider. The Service does not recommend the self-management of health problems. Information obtained by using the Service is not exhaustive and does not cover all aspects of the disease or their treatment. Should you have any healthcare-related questions, please call or see your physician or other healthcare provider promptly. You should never disregard medical advice or delay in seeking it because of something you have read here.

Monogram Biosciences Safe Harbor Statement
This Web site contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this Web site that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the development of future products; the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger studies involving tumor samples will yield favorable results regarding the predictive capability of eTag assays for responsiveness to cancer drugs; our ability to establish reliable, high-volume operations at commercially reasonable costs; our ability to introduce new products commercially; our ability to successfully integrate the operations of ACLARA into our operations; competition from larger more established diagnostic providers; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the level of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for our products; whether the FDA or any other agency will seek to regulate Monogram's in-house clinical laboratory testing; our ability to comply with FDA regulations in order to establish and maintain diagnostic kit manufacturing operations; whether we will encounter problems or delays in establishing and validating eTag assays within our clinical laboratory; whether we will encounter problems or delays in automating our processes or expanding our capacity; whether the intellectual property underlying the Company's technology is adequate; whether we may be deemed to infringe on the intellectual property of others and whether licenses to third-party technology will be available; whether Monogram is able to build brand loyalty and expand revenues; the potential impact of any payments under the CVRs on our common stock and capital resources; and whether Monogram will be able to raise sufficient capital when required. For a discussion of other factors that may cause Monogram's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.